IR@PKUHSC  > 北京大学第三临床医学院  > 普通外科
学科主题临床医学
Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis
Rao, Wensheng; Wu, Xuejie2; Xiu, Dianrong1
关键词hepatitis B immunoglobulin hepatitis B virus recurrence lamivudine liver transplantation YMDD mutant
刊名TRANSPLANT INTERNATIONAL
2009-04-01
DOI10.1111/j.1432-2277.2008.00784.x
22期:4页:387-394
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Surgery ; Transplantation
研究领域[WOS]Surgery ; Transplantation
关键词[WOS]VIRUS RECURRENCE ; IMMUNE GLOBULIN ; PREVENTION ; INFECTION ; WITHDRAWAL ; RESISTANCE ; RECIPIENTS ; OUTCOMES ; ERA
英文摘要

There is a controversy over whether the different outcomes of prophylaxis of hepatitis B virus (HBV) recurrence are attributable to different treatments. A systematic review and a meta-analysis were conducted to evaluate lamivudine monotherapy and combined therapy of lamivudine and hepatitis B immunoglobulin (HBIG) in HBV infected liver recipients. A fixed effects model was used for statistical pooling of relative risks (RR) for the different outcomes. Six articles (551 patients) fulfilled the inclusion criteria. Statistically significant differences were observed between lamivudine monotherapy and lamivudine + HBIG therapy in hepatitis B recurrence [P < 0.0001; RR = 0.38; 95% CI (0.25, 0.58)], YMDD mutant [P = 0.002; RR = 0.40; 95% CI (0.23, 0.72)] and hepatitis B recurrence in HBV-DNA positive patients before orthotopic liver transplantation [P < 0.00001; RR = 0.31; 95% CI (0.21, 0.45)]. No significant differences were observed in patient survival [P = 0.59; RR = 1.02; 95% CI (0.95, 1.09)], graft survival [P = 0.56; RR = 1.02; 95% CI (0.95, 1.09)] and diseases leading to death between the two groups [HBV recurrence leading to death: P = 0.05; RR = 0.47; 95% CI (0.22, 1.02); hepatocellular carcinoma recurrence leading to death: P = 0.13; RR = 0.34; 95% CI (0.09, 1.36)]. In conclusion, combination of lamivudine and HBIG can effectively decrease the recurrence rate of HBV and the incidence of YMDD mutant, but it can not improve patient survival and graft survival significantly. Well-designed large-sample trials are needed to evaluate the efficiency of combined therapy of lamivudine and HBIG in prophylaxis of HBV recurrence in liver graft recipients.

语种英语
WOS记录号WOS:000263911400004
引用统计
被引频次:37[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64641
专题北京大学第三临床医学院_普通外科
作者单位1.Peking Univ, Hosp 3, Dept Gen Surg, Beijing 100083, Peoples R China
2.Peking Univ, Hosp 1, Beijing 100083, Peoples R China
推荐引用方式
GB/T 7714
Rao, Wensheng,Wu, Xuejie,Xiu, Dianrong. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis[J]. TRANSPLANT INTERNATIONAL,2009,22(4):387-394.
APA Rao, Wensheng,Wu, Xuejie,&Xiu, Dianrong.(2009).Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis.TRANSPLANT INTERNATIONAL,22(4),387-394.
MLA Rao, Wensheng,et al."Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis".TRANSPLANT INTERNATIONAL 22.4(2009):387-394.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Rao, Wensheng]的文章
[Wu, Xuejie]的文章
[Xiu, Dianrong]的文章
百度学术
百度学术中相似的文章
[Rao, Wensheng]的文章
[Wu, Xuejie]的文章
[Xiu, Dianrong]的文章
必应学术
必应学术中相似的文章
[Rao, Wensheng]的文章
[Wu, Xuejie]的文章
[Xiu, Dianrong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。